Quick answer
Retatrutide is investigational, while semaglutide and tirzepatide are drug ingredients; they should not be presented as cosmetic microneedle patch OEM products.
Quick answer
We do not offer retatrutide, semaglutide, tirzepatide or other GLP-1 drug ingredients as cosmetic microneedle patches, private-label skincare products or weight-loss patches. A microneedle delivery format does not turn a drug program into a cosmetic product.
What is retatrutide?
As of September 2026, Eli Lilly describes retatrutide as an investigational GIP, GLP-1 and glucagon triple receptor agonist. Lilly states that it is not FDA-approved, is not available for public use and is being studied as a once-weekly subcutaneous injection in clinical trials. A product marketed online as a retatrutide patch should not be assumed to be authorized, authentic, safe or effective.
Why semaglutide and tirzepatide are different from cosmetic peptides
Semaglutide and tirzepatide are associated with regulated drug products and treatment indications. FDA has repeatedly warned about unapproved GLP-1 products, misleading claims and products sold outside the legitimate drug supply chain. Cosmetic peptides used for appearance-focused skincare have a different intended use and require their own ingredient, safety and claim assessment.
Does the patch format change the classification?
No delivery format creates an automatic cosmetic pathway. Classification depends on composition, intended use, claims, mechanism, presentation and the destination jurisdiction. Claims involving weight loss, diabetes, appetite, systemic hormone receptors or treatment of disease are drug claims, not cosmetic eye-care claims.
What we can develop instead
For cosmetic eye-care projects, consider compatibility-led concepts such as copper peptide microneedle eye patches, acetyl hexapeptide-8 eye patches or multi-peptide eye patches. The final formula, eye-area safety, evidence, claims and market eligibility must still be reviewed.
Buyer due-diligence questions
- Is the ingredient a cosmetic raw material, an approved drug ingredient or an investigational molecule?
- What intended use and claims appear on the website, label and sales materials?
- Does the proposed manufacturer have the appropriate legal pathway and quality system for that category?
- Is the product being presented as equivalent to an approved drug without authorization?
- Has qualified regulatory counsel reviewed the complete product and target market?
Official sources
- Eli Lilly: What to know about retatrutide
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss
- FDA warning letter addressing retatrutide, semaglutide and tirzepatide marketing